Johnson & Johnson has set aside $3 billion to deal with the legal fallout from 93,000 all-metal hip implants recalled in 2010, according to a story in the Chicago Tribune. But the healthcare giant may face even more expenses down the line from more problems with a new line of hip implants.
The company’s DePuy Orthopaedics division is facing 3,000 lawsuits filed over the recalled model. And a subsequent model that ...
continue reading...
The Wall Street Journal reports that Johnson & Johnson and federal prosecutors have reached a settlement over allegations that the company illegally marketed its antipsychotic drug Risperdal and other medications.
That settlement will reportedly be about $2.2 billion, and include about $400 million in criminal fines.
But the settlement won’t be the end of Johnson & Johnson’s legal troubles. It’s still facing thousands of lawsuits from plaintiffs alleging that the company’sread more.... --> continue reading...
The New York Times reports that the U.S. Food and Drug Administration conducted a wide-ranging surveillance operation against its own scientists.
The agency used “spy software” designed to help employers monitor workers, and captured screen images from the government laptops of scientists as they were being used at work or at home.
Though federal agencies have broad discretion to monitor their employees’ computer use, the F.D.A. program may have crossed legal lines ...
continue reading...
Stryker Corp. of Kalamazoo, Mich., has announced a voluntary recall of components used in metal hip joints.
A report on CBS 62 in Detroit says Stryker’s Rejuvenate and ABG II modular-neck stems, despite their names, are used in hip implants.
Stryker said the recall was based on reports from the field of corrosion and “fretting,” which is corrosion made worse by abrasive wear. A Stryker news release says: “These risks include the ...
continue reading...Johnson & Johnson will reportedly pay a settlement in the neighborhood of $2 billion to settle federal charges that the company used illegal tactics in marketing its antipsychotic drug Risperdal.
The federal probe prompting that settlement included investigations into the company’s alleged kickbacks to Omnicare Inc., a company that dispenses drugs at nursing homes, to boost sales of certain medicines.
In light of Johnson & Johnson’s enormous profits, some observers have questioned ...
continue reading...
